Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | PRNP | P04156 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21890500 | 1.00 | GPR3 (0.39) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL21890644 | 0.97 | GPR3 (0.39) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL21890645 | 0.97 | GPR3 (0.39) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL21298141 | 0.96 | GPR3 (0.38) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL21298063 | 0.93 | GPR3 (0.38) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL21890493 | 0.93 | GPR3 (0.40) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL22223109 | 0.92 | GPR3 (0.39) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL22223108 | 0.92 | GPR3 (0.39) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL21890357 | 0.90 | GPR3 (0.40) | GPR3MAPTALDH1A1HPGDRAB9A | |
| SCHEMBL21890378 | 0.89 | KDM4E (0.39) | GPR3MAPTALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230068759-A1 | DONOR-ACCEPTOR TYPE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIALS BASED ON IMIDAZO[1,2-F]PHENANTHRIDINE AND ANALOGUES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2023-03-02 | — | — | US | disclosed |
| US-20200227656-A1 | DONOR-ACCEPTOR TYPE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIALS BASED ON IMIDAZO[1,2-F]PHENANTHRIDINE AND ANALOGUES | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2020-07-16 | — | — | US | disclosed |
| US-10615349-B2 | Donor-acceptor type thermally activated delayed fluorescent materials based on imidazo[1,2-F]phenanthridine and analogues | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2020-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200227656-A1 | DONOR-ACCEPTOR TYPE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIALS BASED ON IMIDAZO[1,2-F]PHENANTHRIDINE AND ANALOGUES | SUN2, STAU1, HELZ | GPR3 1777/4885MAPT 2512/4885ALDH1A1 558/4885 |
| US-20230068759-A1 | DONOR-ACCEPTOR TYPE THERMALLY ACTIVATED DELAYED FLUORESCENT MATERIALS BASED ON IMIDAZO[1,2-F]PHENANTHRIDINE AND ANALOGUES | SUN2, STAU1, HELZ | GPR3 1777/4885MAPT 2512/4885ALDH1A1 558/4885 |
| US-10615349-B2 | Donor-acceptor type thermally activated delayed fluorescent materials based on imidazo[1,2-F]phenanthridine and analogues | SUN2, STAU1, HELZ | GPR3 1777/4885MAPT 2512/4885ALDH1A1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.